SequelSEC

Zentalis Pharmaceuticals, Inc. ZNTL

Pharmaceutical Preparations · CIK 0001725160 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$152.81M
Fiscal year ended 2025-12-31
Free cash flow
-$125.25M
Fiscal year ended 2025-12-31

Zentalis Pharmaceuticals, Inc. (ZNTL) reported revenue of $0 and net income of -$137.06M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Zentalis Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Zentalis Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Revenue$0$67.42M$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$152.81M-$191.19M-$299.51M-$227.29M
Net income-$137.06M-$165.84M-$292.19M-$236.81M
Research & development$107.30M$167.77M$189.59M$172.73M
Weighted-average diluted sharesshares 71.87Mshares 71.08Mshares 65.41Mshares 52.86M
Pretax income-$136.62M-$165.69M-$292.91M-$237.58M
Income tax expense$442.00K$177.00K-$601.00K-$469.00K
Diluted EPS$-1.91$-2.33$-4.47$-4.48
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$37.72M$87.12M$64.35M$54.55M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Zentalis Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Cash & equivalents$36.00M$33.90M$28.04M$43.07M
Total assets$288.97M$430.34M$551.69M$539.31M
Current assets$253.19M$386.07M$496.72M$451.93M
Total liabilities$72.76M$93.15M$114.30M$105.29M
Current liabilities$36.56M$52.72M$69.37M$56.65M
Total equity incl. NCI$216.20M$337.19M$437.39M$434.02M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivable$0$5.00M$0Unavailable
GoodwillUnavailable$0$3.74M$3.74M
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payable$7.21M$7.44M$14.93M$11.25M

Cash flow

Zentalis Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Operating cash flow-$125.25M-$170.86M-$207.82M-$163.75M
Capital expenditures$0$221.00K$583.00K$2.55M
Investing cash flow$131.62M$176.56M-$44.46M-$114.18M
Financing cash flow-$4.28M$108.00K$237.30M$261.04M
Net change in cash$2.09M$5.81M-$14.98M-$16.89M
Stock-based compensation$20.72M$67.27M$54.82M$46.84M
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchases$9.98M$0$0Unavailable
Depreciation & amortization$739.00K$1.29M$1.39M$1.43M

Derived

Zentalis Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Free cash flow-$125.25M-$171.08M-$208.40M-$166.30M
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailable-283.6%UnavailableUnavailable
FCF marginUnavailable-253.7%UnavailableUnavailable
SBC / revenueUnavailable99.8%UnavailableUnavailable
Current ratio6.93x7.32x7.16x7.98x
Revenue YoY growth-100.0%UnavailableUnavailableUnavailable
Net marginUnavailable-246.0%UnavailableUnavailable
R&D / revenueUnavailable248.8%UnavailableUnavailable
CapEx / revenueUnavailable0.3%UnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ZNTL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.